Active substance
Silver sulfadiazine
- US FDA 5
- US price lines 14
- WHO EML 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SILVADENE | 1% | cream · topical | KING PHARMS LLC | Prescription | 26 Nov 1973 |
| SSD | 1% | cream · topical | DR REDDYS | Prescription | 25 Feb 1982 |
| THERMAZENE | 1% | cream · topical | THEPHARMANETWORK LLC | Prescription | 23 Dec 1985 |
| SSD AF | 1% | cream · topical | DR REDDYS | Discontinued | 25 Feb 1982 |
| SILDAFLO | 1% | dressing · topical | FRANKLIN PHARMS | Discontinued | 30 Nov 1989 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SILVADENE 1% CREAM | $0.43283 | per GM | 19 Aug 2026 |
| US NADAC | SILVADENE 1% CREAM | $0.28856 | per GM | 1 Jul 2026 |
| US NADAC | SILVADENE 1% CREAM | $0.12469 | per GM | 1 Jul 2026 |
| US NADAC | SILVADENE 1% CREAM | $0.23076 | per GM | 23 Sep 2026 |
| US NADAC | SILVADENE 1% CREAM | $0.27318 | per GM | 1 Jul 2026 |
| US NADAC | SILVER SULFADIAZINE 1% CREAM | $0.40717 | per GM | 23 Sep 2026 |
| US NADAC | SILVER SULFADIAZINE 1% CREAM | $0.31774 | per GM | 23 Sep 2026 |
| US NADAC | SILVER SULFADIAZINE 1% CREAM | $0.12781 | per GM | 23 Sep 2026 |
| US NADAC | SILVER SULFADIAZINE 1% CREAM | $0.25963 | per GM | 23 Sep 2026 |
| US NADAC | SILVER SULFADIAZINE 1% CREAM | $0.2609 | per GM | 23 Sep 2026 |
| US NADAC | SSD 1% CREAM | $0.31774 | per GM | 23 Sep 2026 |
| US NADAC | SSD 1% CREAM | $0.12781 | per GM | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.2. Dermatological medicines > Anti-infective medicines · core
Burns
Local > Topical > Cream: 1%
Safety signals and safety-related labeling changes
- US FDA 1 Aug 2016 SILVADENE — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.